These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 12236622

  • 1. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B.
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [Abstract] [Full Text] [Related]

  • 2. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 3. Examining the efficacy of biologic therapy: are there real differences?
    Fleischmann RM.
    J Rheumatol Suppl; 2002 Sep; 65():27-32. PubMed ID: 12236619
    [Abstract] [Full Text] [Related]

  • 4. The mode of action of cytokine inhibitors.
    Arend WP.
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [Abstract] [Full Text] [Related]

  • 5. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V, Kavanaugh AF.
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [Abstract] [Full Text] [Related]

  • 6. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 7. Biologics in rheumatoid arthritis.
    Sharma PK, Hota D, Pandhi P.
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [Abstract] [Full Text] [Related]

  • 8. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 9. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB.
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [Abstract] [Full Text] [Related]

  • 10. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S, Burmester GR.
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [Abstract] [Full Text] [Related]

  • 11. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A, Perniok A.
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [Abstract] [Full Text] [Related]

  • 12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J.
    Scand J Rheumatol; 2006 Dec; 35(3):182-8. PubMed ID: 16766364
    [Abstract] [Full Text] [Related]

  • 14. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 15. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, Emery P.
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [Abstract] [Full Text] [Related]

  • 16. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    Schwartzman S, Fleischmann R, Morgan GJ.
    Arthritis Res Ther; 2004 Mar; 6 Suppl 2(Suppl 2):S3-S11. PubMed ID: 15228615
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D.
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [Abstract] [Full Text] [Related]

  • 18. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH.
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [Abstract] [Full Text] [Related]

  • 19. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 20. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A, Kotulska A, Giebel S, Cader SA, Kucharz EJ.
    Przegl Lek; 2002 Sep; 59(11):916-8. PubMed ID: 12715722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.